Frontlight ResearchEarly access
CompletedPhase 2
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Burkina Faso, Côte d’Ivoire, Gabon, Ghana, Kenya, Rwanda, and Uganda13 sites in 7 countriesChoose a country to see its sites
- Trial code
- NCT07811882
- 2022-004197-27
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 95 people enrolled
- Started
- 10 Oct 2025
- Ended
- 1 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- KAE609 (Cipargamin)
- SoC (Coartem)
- INE963
- Record updated
- 10 September 2026
Who can take part
- Age
- 12 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Male and female patients ≥12 years of age at screening
- Patients must have acute uncomplicated P. falciparum malaria mono infection at screening confirmed by a parasite count between 1,000 to 150,000 asexual parasite count/μl of blood for P. falciparum
- Patients must weigh between 35 kg and 90 kg at screening
- Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history of fever during the previous 24 hours
Who cannot take part
- Patients with signs and symptoms of severe/complicated malaria at screening or mixed Plasmodium infection (i.e., infection with more than one malaria species) at screening
- Any known/suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection at screening
- Moderate to severe anemia, chronic hemoglobinopathy (Hemoglobin level < 8 g/dL), or known chronic underlying disease such as sickle cell disease at screening
- Known clinically significant liver disease (e.g., chronic hepatitis, liver cirrhosis (compensated or decompensated), history of hepatitis B or C, hepatitis A or B vaccination in the last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis. Clinical or laboratory evidence of any of the following at screening:; AST/ALT > 3 x the upper limit of normal range (ULN), regardless of the level of total bilirubin; AST/ALT > 1.5 and ≤ 2 x ULN and total bilirubin is > ULN; Total bilirubin > 2 x ULN, regardless of the level of AST/ALT
- History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study such as:; Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker; History of familial long QT syndrome or known family history of Torsades de Pointe; Resting heart rate (physical exam or 12 lead ECG) < 50 bpm; Other protocol-defined inclusion/exclusion criteria may apply
- Pregnant or nursing (lactating) women, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of effective contraception, and sexually active patients not willing to practice effective contraception
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.
The 2 groups in the trial
- Cohort B1: Cipargamin + INE963Treatment being tested
Treatment: KAE609 (Cipargamin) and INE963
- Cohort B1: SoC (Artemether 80 mg + lumefantrine 480 mg)Existing treatment, for comparison
Treatment: SoC (Coartem)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria
- Record updated
- 10 September 2026